Skip to main content

Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials

Parker AB, Naylor CD. Am Heart J. 2000; 139(6):952-61.

Background — The objective of this study was to determine how subgroup analyses are performed in large randomized trials of cardiovascular pharmacotherapy.

Methods and Results — We reviewed 67 randomized, double-blind, controlled trials involving pharmacotherapy in at least 1000 patients with unstable angina, myocardial infarction, left ventricular dysfunction, or heart failure with clinical outcomes as primary end points, published between 1980 and 1997. Nine had no subgroup analyses but 43 reported on 5 or more subgroups and 31 reported subgroups without formal statistical tests for treatment-subgroup interactions. In most trials, a rationale for subgroup selection was missing. All but 6 focused on single-factor subgroups.

Conclusions — Trial subgroups should ideally be defined a priori on 2 bases: single-factor subgroups with a strong rationale for biological response modification and multifactorial prognostic subgroups defined from baseline risks. However, single-factor subgroup analyses are often reported without a supporting rationale or formal statistical tests for interactions. We suggest that clinicians should interpret published subgroup-specific variations in treatment effects skeptically unless there is a prespecified rationale and a significant treatment-subgroup interaction.

Keywords: Cardiovascular diseases Pharmacotherapy Clinical trials